Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Number of holders
-
46
-
Total 13F principal, excl. options
-
404,135,300
-
Principal change
-
+3,434,100
-
Total reported value, excl. options
-
$404,330,916
-
Value change
-
+$2,267,998
-
Number of buys
-
29
-
Number of sells
-
-21
-
Price
-
$0.9987
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q4 2017
54 filings reported holding 09061GAH4 - BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q4 2017.
BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 has 46 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $404,135,300 of principal
.
Largest 10 bondholders include CNH PARTNERS LLC ($41,850,000 of principal), Allianz Asset Management GmbH ($41,755,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($37,456,000 of principal), ROYAL BANK OF CANADA ($34,300,000 of principal), Myriad Asset Management Ltd. ($17,500,000 of principal), SHENKMAN CAPITAL MANAGEMENT INC ($16,159,000 of principal), FMR LLC ($15,550,000 of principal), STATE STREET CORP ($15,100,000 of principal), BAKER BROS. ADVISORS LP ($15,000,000 of principal), and JPMORGAN CHASE & CO ($12,117,000 of principal).
This table shows the top 46 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.